In fact, gain-of-function mutations in PI3K have been found in nearly one-third of all human CRCs.1–4 Reports have shown that mutations in p110α, the catalytic subunit of PI3K, increase cell migration and the invasive capability of tumor cells.5,6In vivo studies have demonstrated that cells bearing p110α mutations in PI3K were more metastatic than cells carrying wild-type (WT) PI3K in an orthotopic mouse model of colon cancer.7 Clinically, studies have shown a significant correlation between the mutations in PIK3CA, the p110α-encoding gene, and the survival of CRC patients. This evidence concerns the gene PIK3CA and colorectal carcinoma.